Categories
Health

U.S. to start extensive distribution of third vaccine doses subsequent month

The United States will begin distributing Covid-19 booster vaccinations on a large scale next month as new data shows vaccine protection wears off over time, US health officials said on Wednesday.

It is now “very clear” that immunity declines after the first two doses, and with the dominance of the delta variant, “we see evidence of decreased protection against mild and moderate disease,” according to the CDC. signed declaration Director Dr. Rochelle Walensky, Acting FDA Commissioner Dr. Janet Woodcock, the White House Senior Medical Advisor, Dr. Anthony Fauci, and other US health leaders.

“Based on our latest assessment, current protection against serious illness, hospitalization and death could decline in the coming months, especially for those at higher risk or who were vaccinated during the earlier stages of vaccination.”

As a result, U.S. authorities are preparing to offer booster shots to all eligible Americans starting the week of September 20, eight months after their second dose of Pfizer or Moderna vaccines, officials said. While they said recipients of the Johnson & Johnson single vaccine will likely need booster vaccinations, they are waiting for more dates in the next few weeks before making a formal recommendation.

“With this data, we will also keep the public informed with a timely schedule for J&J booster shots,” officials said.

The plan is subject to formal recommendation by a CDC Vaccine Advisory Committee and FDA approval, also a formality.

The announcement came ahead of a Covid press conference at the White House on Wednesday, where federal health officials further outlined their plan for boosters. President Joe Biden is expected to speak about the U.S. efforts after the briefing, the White House told reporters on Tuesday.

The decision to recommend booster vaccinations comes as the public becomes increasingly concerned about the Delta variant and an increase in breakthrough cases – infections in fully vaccinated individuals. It marks a departure from previous comments by U.S. health officials who said in recent months that fully vaccinated Americans did not need a booster at this point.

U.S. officials changed their embassy to boosters in the past few days as cases continued to rise. Fauci said Thursday that everyone is “likely” to need a booster at some point. On Friday, federal officials approved the administration of booster shots to Americans with compromised immune systems, which include cancer and HIV patients, as well as people who have had organ transplants.

The director of the National Institutes of Health, Dr. Francis Collins, who also signed the statement, said Tuesday that new Covid data, including from Israeli health officials, had caused US health leaders to reconsider their position on vaccine boosters. Israel on Monday released new data showing a reduction in the effectiveness of Pfizer’s Covid vaccine against serious illness in people 65 and over who were fully vaccinated in January or February.

There are similar trends in vaccine effectiveness in the United States, Collins said. He said the surge in breakthrough cases could be due to a combination of the rapidly spreading Delta variant and the deterioration in Covid vaccine protection over time.

The effectiveness of Pfizer’s Covid vaccine has steadily declined over time, dropping to around 84% around four to six months after receiving the second dose for vaccinated people, according to CEO Albert Bourla. Moderna said his vaccine remained 93% effective for the first six months after the second dose, but expects protection to decrease and boosts to be needed.

During a news conference on Wednesday, Walensky said officials based their decision on studies showing immunity to Pfizer and Moderna vaccines decreased over several months. A study in New York from May 3 to July 25 showed that the vaccine’s effectiveness in protecting against infection decreased from around 92% to 80%. Another study by the Mayo Clinic showed that the effectiveness of Pfizer’s vaccine decreased from around 76% to 42%, while that of Moderna’s decreased from 86% to 76%.

“Right now, it’s still like our vaccine protection is working really well,” said Collins. “But we don’t want to wait until it’s oh, too late.”

The move to recommend boosters is likely to trigger criticism, especially since a large part of the world population has not even received a dose of a Covid vaccine.

Earlier this month, the World Health Organization urged rich nations to stop distributing booster vaccinations until at least the end of September to allow poorer countries to vaccinate their populations with the first rounds of vaccination. The application is part of WHO Director General Tedros Adhanom Ghebreyesus’ plan to vaccinate 40% of the world’s population by December.

The US released the statement minutes after the WHO condemned wealthy nations who support boosters for the general public.

“We clearly believe that the data so far does not suggest the need for boosters,” said Dr. Soumya Swaminathan, WHO senior scientist, during a press conference. “And we need to know which groups and at what point in time after the vaccination and which specific vaccinations the people received in their basic course.”

Lawrence Gostin, director of the WHO Collaborating Center for National and Global Health Law, called the US booster shot plan “a slap in the face” of the international health agency.

“There is a better way to create a win-win situation,” he said in a telephone interview. “We should only empower our health workers and vulnerable people. At the same time, Biden should undertake a bold campaign to vaccinate the world, including significantly increased donations and an increase in vaccine production. “

“In this way we are doing good to America and good to the world. It is in our national interest to stop the development of even more dangerous varieties,” he added.

During a briefing at the White House Tuesday, press secretary Jen Psaki said the government believes it can empower the American people while ensuring that the rest of the world is vaccinated.

“We believe this is a wrong decision. We can do both,” said Psaki. “The United States is by far the largest contributor to the global fight against Covid. We will continue to be the vaccine arsenal around the world. We also have enough supplies and had planned long enough should a refresher be required for those eligible. “Population.”

Giving third shots appears safe. Early data from small studies on the effects of booster doses in immunocompromised patients showed no serious side effects from a third vaccination with an mRNA vaccine, nor did recipients develop side effects beyond those already seen after the initial two-dose treatment.

Once the booster is approved, nursing home residents, health care providers and the elderly – the first groups to be vaccinated in December and January – will likely be given priority for additional vaccinations, Collins said Tuesday. He said “ideally” people should stick with the same manufacturer that they got their first two doses from.

“But if for some reason you don’t have access to it, get the other one,” he said. “Again, as a scientist, I would be more comfortable fixing our plans on real dates, and that means sticking to the same type of vaccine that you had to start with.”

– CNBC’s Rich Mendez and Robert Towey contributed to this report.

Categories
Health

Vaccine Booster Shot Distribution to Start Subsequent Month in US

The Biden administration on Wednesday outlined a plan for Americans who received the Pfizer-BioNTech and Moderna coronavirus vaccines to get a booster shot eight months after receiving their second doses, starting Sept. 20.

Health care workers, nursing home residents and other older adults who were vaccinated early will be first in line, starting then, contingent on authorization by federal regulators. “We are starting to see evidence of reduced protection against mild and moderate disease,” officials of several federal agencies said in a prepared statement.

“Here’s what you need to know: If you are fully vaccinated, you still have a high degree of protection from the worst outcomes of Covid-19, severe disease hospitalization and death,” Dr. Vivek Murthy, the surgeon general, said at a White House briefing.

“We are not recommending that you go out and get a booster today. Instead, starting the week of Sept. 20,” he added, but that fully vaccinated adults should “begin getting their booster shots eight months after their second shot of an mRNA vaccine.”

Protection conferred by the vaccines against severe disease, hospitalization and death could diminish in the months ahead, especially among high-risk groups who were vaccinated early, the officials said. “For that reason, we conclude that a booster shot will be needed to maximize vaccine-induced protection and prolong its durability.”

Still, Dr. Rochelle Walensky, the C.D.C. director, sought to be reassuring. “These data confirm that while protection against infection may decrease over time, protection against severe disease and hospitalization is currently holding up pretty well,” she said.

People who received the Johnson & Johnson vaccine may also require additional doses. But that vaccine was not rolled out until March 2021, and a plan to provide boosters for those individuals will be made after reviewing new data expected over next few weeks, officials said.

Some experts immediately pushed back against the decision, saying only some older adults and people with weakened immune systems needed extra protection. The World Health Organization has asked that wealthy countries defer distributing booster shots until the end of September.

Jeff Zients, the White House pandemic coordinator, said at the briefing on Wednesday that the administration is on its way to donating more than 600 million doses of vaccines to other countries.

“We’re going to do both,” he said. “We’re going to both protect the American people and we’re going to do more and more to help vaccinate the world. ”

Before Americans can begin to receive boosters, the Food and Drug Administration must first authorize a third dose of the mRNA vaccines made by Pfizer-BioNTech and Moderna, and an advisory committee of the Centers for Disease Control and Prevention must review the evidence and make recommendations.

Federal officials plan to begin by offering booster shots directly to residents of long-term care facilities, since the vaccines were distributed to this population early in the rollout and the virus poses a particular threat to the elderly.

“We will continue to follow the science on a daily basis, and we are prepared to modify this plan should new data emerge that requires it,” federal officials said.

Still, “there’s nothing magical about this number,” Dr. Murthy said, referring to the recommendation to get a booster eight months after the second dose. “This is where judgment comes in.”

Categories
Health

WHO says Covid is spreading quicker than the worldwide distribution of vaccines

Funeral directors wearing personal protective equipment carry a coffin during the funeral of a COVID-19 victim amid a coronavirus disease (COVID-19) nationwide lockdown at Olifantsvlei Cemetery, southwest of Joburg, South Africa, Jan. 6, 2021.

Siphiwe Sibeko | Reuters

The global spread of Covid-19 is advancing faster than the global distribution of vaccines, World Health Organization officials said on Monday.

They attributed transmission rates to new variants like Alpha and Delta, which have proven to be more contagious.

“This means that the risks for people who are not protected, ie most of the world’s population, have increased,” WHO Director General Tedros Adhanom Ghebreyesus said during a press conference.

While the number of new cases of the virus continues to decline worldwide, the number of deaths has not decreased by the same amount, he said. Since the pandemic began, more than 3.8 million people have died of Covid worldwide.

A person receives a dose of Pfizer BioNTech vaccine at a vaccination center for people over 18 years old at the Belmont Health Center in Harrow amid the coronavirus disease (COVID-19) outbreak in London, Great Britain, June 6, 2021.

Henry Nicholls | Reuters

The number of new cases has declined for seven straight weeks, the longest decline in the world since the pandemic began. But the number of deaths reported this week is still similar to last week, he said.

“While weekly cases are at their lowest level since February, deaths are not falling anytime soon,” Tedros said. “The global decline hides worrying increases in cases and deaths in many countries.”

Countries in Africa have higher Covid death rates than other countries, he said. The higher death rates are particularly worrying as African countries have reported fewer cases than most other regions.

African countries also have the least access to vaccines, diagnostics and oxygen supplies, underscoring the impact of medical inequality that global health authorities have warned about.

“There are enough vaccine doses around the world to contain transmission and save many lives when used in the right places for the right people,” said Tedros.

The G-7 have pledged to distribute 870 million doses of vaccine around the world, but WHO says more are needed.

“This is a big help, but we need more and we need it faster. More than 10,000 people die every day,” said Tedros.

Categories
Health

U.S. to debate wider distribution, India calls to waive patent protections

Ground staff unload coronavirus disease (COVID-19) supplies from the United States at the cargo terminal of Indira Gandhi International Airport on April 30, 2021 in New Delhi, India.

Prakash Singh | Reuters

WASHINGTON – White House Chief of Staff Ron Klain said Sunday that the Biden government plans to distribute the coronavirus vaccine to India and other countries after millions of Americans received their doses.

In the past few weeks, India has been grappling with a staggering surge in new coronavirus infections. Over the weekend, India reported 400,000 cases a day for a cumulative total of 19,557,457 cases. This is evident from numbers compiled by Johns Hopkins. The spike may have been triggered by a highly contagious variant of Covid known as B.1.617, which was first identified in the country.

The variant has since been identified in other countries, including the United States.

On Friday, the White House announced it would limit travel from India as the country works to counter the rise in Covid-19 infections.

“We are rushing to help India,” said Klain during an interview on CBS’s Face the Nation program.

Klain said the US has sent therapeutics, rapid diagnostic test kits, ventilators and protective equipment to the world’s largest democracy, as well as raw materials that are vital to vaccine production.

“Our US Trade Representative, Katherine Tai, will go to the WTO next week to begin talks on how we can further distribute, license and distribute this vaccine,” he said when asked if the Biden administration would protect patents The coronavirus vaccine would loosen up.

Klain added that he expected the White House to have more to say on the matter in the coming days.

Earlier this month, Indian Prime Minister Narendra Modi discussed with Biden about the revocation of patent protection for the coronavirus vaccine. The relaxation would give governments faster and more affordable access to the life-saving doses.

Last week, the Biden government announced that it would immediately provide the raw materials needed to manufacture coronavirus vaccines in India. The US response came after Britain, France and Germany pledged aid to India, the world’s largest democracy. Rich nations have come under fire in the past few days for hoarding the raw materials needed for the shots.

Categories
Health

J&J Covid vaccine distribution in poor, Black communities raises race questions

Johnson & Johnson Covid-19-Impfstoff in einem Impfzentrum, das am 5. März 2021 im Hilton Chicago O’Hare Airport Hotel in Chicago, Illinois, eingerichtet wurde.

Kamil Krzaczynski | AFP | Getty Images

Logan Patmon aus Detroit weiß, dass der Covid-19-Impfstoff von Johnson & Johnson einfacher zu verteilen ist als die Schüsse von Moderna und Pfizer.

Der 28-jährige Black-Anwalt sagte, er sehe es als minderwertig an, da Daten aus klinischen Studien gezeigt haben, dass J & J in den USA zu 72% gegen Covid schützt, verglichen mit etwa 95% bei den beiden anderen Impfstoffen.

“Warum für 70 gehen, wenn Sie 95 bekommen können?” er sagte.

Für Beamte ist der Schuss von J & J ein Segen, da er monatelang bei Kühlschranktemperatur gelagert werden kann und nur eine Dosis benötigt – im Gegensatz zu Pfizer und Moderna, für die Gefrierschränke und zwei Runden Stöße im Abstand von etwa einem Monat erforderlich sind. Das macht J & Js Schuss zu einem wichtigen Instrument, um Menschen, die möglicherweise nicht zu einem zweiten Termin zurückkehren können, lebensrettende Impfstoffe zukommen zu lassen. Es ist besonders wertvoll, um die Aufnahmen an schwer erreichbare Orte zu bringen, an denen möglicherweise keine zuverlässige Kühlung vorhanden ist, z. B. in Stammesgebieten, in ärmeren Gegenden sowie in ländlichen und Grenzgemeinden.

“Nur weil es am einfachsten ist, heißt das nicht, dass es das Richtige ist”, sagte Patmon gegenüber CNBC. “Sie möchten nicht, dass es eine Situation gibt, in der getrennte, wohlhabendere Gebiete den besseren Impfstoff erhalten und den armen, mehr Minderheitengebieten gesagt wird: ‘Sei einfach glücklich.'”

Beamte stoßen bei der Verteilung der Aufnahmen von J & J auf ein unvorhergesehenes Problem. Obwohl unbeabsichtigt, stellen einige Leute aufgrund ihrer niedrigeren Wirksamkeitsrate die Frage, ob dies nur ein weiteres Beispiel für eine subtil rassistische Behandlung von Minderheiten in Amerika ist. Während der Impfstoff von J & J hochwirksam ist, insbesondere gegen schwere Krankheiten und Todesfälle, sehen Patmon und andere Amerikaner ihn immer noch als minderwertig an. Durch den Versand an ärmere Postleitzahlen in Großstädten und ländlichen Gemeinden riskieren Beamte laut Gesundheitsexperten Vorwürfe der Diskriminierung.

Dies könnte das Vertrauen in die Einführung von Impfstoffen weiter untergraben, insbesondere in Farbgemeinschaften, sagen Experten, da mehr Daten aus Staaten zeigen, dass Schwarze und Hispanics weiterhin einen überproportionalen Anteil an Covid-19-Todesfällen ausmachen, die Impfstoffe jedoch mit deutlich geringeren Raten erhalten als Weiße Menschen.

In New York zum Beispiel machen Schwarze etwa 16% der Bevölkerung des Bundesstaates aus und machen 23% der Todesfälle durch Covid-19 aus, haben aber laut einem Bericht des gemeinnützigen Kaisers vom 3. März bisher nur 8% der Schüsse erhalten Family Foundation, die staatlich gemeldete Daten analysierte. Hispanics machen 19% der Bevölkerung und 23% der Todesfälle in Covid aus, haben aber nur 9% der Schüsse erhalten.

Weiße Menschen machen 63% der Bevölkerung und 40% der Todesfälle aus, aber laut KFF-Analyse haben sie 81% der Impfungen erhalten.

Die Verwendung des Impfstoffs von J & J hauptsächlich in schwer erreichbaren Gebieten kann zu einem “Maß an Misstrauen” und “erhöhtem Zögern” führen, sagte Dr. Sonja Hutchins, eine ehemalige CDC-Beamtin, am 1. März gegenüber dem Beratenden Ausschuss für Immunisierungspraktiken der Agentur sehr vorsichtig zu sein und zu verstehen, was einige der unbeabsichtigten Folgen der Ausrichtung auf Farbgemeinschaften sein könnten, von denen einige glauben, dass sie schwer zu lesen sind, wenn sie erreichbar sind “, sagte Hutchins, der jetzt Professor an der Morehouse School of Medicine ist.

Impfstoffe vergleichen

Der Impfstoff von J & J wurde am 27. Februar für die Verwendung in den USA zugelassen. Der J & J-Schuss zeigte in den USA etwa einen Monat nach der Inokulation eine Wirksamkeit von 72%, 66% in Lateinamerika und 64% in Südafrika, wo das ansteckendere und virulentere B. Die Variante .1.351 breitet sich schnell aus. Insbesondere verhinderte es 100% der virusbedingten Krankenhausaufenthalte und Todesfälle. Die klinischen Phase-3-Studien von Pfizer und Moderna, die im November abgeschlossen wurden, zeigten, dass beide Impfstoffe eine Wirksamkeitsrate von etwa 95% aufwiesen.

Die Berechnung der Wirksamkeit eines Impfstoffs ist schwierig und kann variieren, je nachdem, wo die Studie durchgeführt wird, welche Arten von Varianten in der Region vorherrschen und wie weit die Gemeinschaft verbreitet ist.

Die dritte Phase der Studie von J & J begann ungefähr zwei Monate hinter der von Pfizer und Moderna und wurde weltweit und in Ländern durchgeführt, in denen bereits infektiösere Varianten, die sich den Impfstoffen entziehen können, bereits eingesetzt hatten.

Dr. Anthony Fauci, Chefarzt des Weißen Hauses, sagte, es sei unmöglich, die drei zu vergleichen, da sie nicht in direkten klinischen Studien bewertet wurden.

“Wir sagen also nicht, dass einer besser oder schlechter ist als der andere, wir sagen, dass alle drei wirklich ziemlich gut sind”, sagte er am Samstag gegenüber MSNBC. “In Bezug auf die Verbreitung in verschiedenen Gruppen hat der Präsident sehr, sehr deutlich gemacht, dass wir Gerechtigkeit haben werden, was bedeutet, dass wir diese gleichmäßig auf die verschiedenen Komponenten verteilen werden, genauso wie wir es mit den anderen beiden getan haben . “

Er sagte, jemand könnte den Impfstoff von J & J bevorzugen, weil nur ein Schuss erforderlich ist, “aber es wird keine absichtliche Versendung an eine demografische Gruppe gegenüber einer anderen geben”, sagte er.

Die Bundesregierung hat letzte Woche fast 4 Millionen Dosen des Impfstoffs von J & J an Bundesstaaten, Apotheken und kommunale Gesundheitszentren verteilt und plant, bis Ende dieses Monats weitere 16 Millionen zu versenden. Das Unternehmen hat bis Ende Juni einen Vertrag mit der US-Regierung über 100 Millionen Dosen abgeschlossen.

Ein wichtiges Verkaufsargument für den Impfstoff von J & J ist, dass er mindestens 3 Monate bei 36 bis 46 Grad Fahrenheit gelagert werden kann und eine Einzeldosis ist. Im Vergleich dazu handelt es sich bei den Impfstoffen von Pfizer und Moderna um zwei Dosierungen. Pfizers Schuss muss in ultrakalten Gefrierschränken gelagert werden, die zwischen minus 112 und minus 76 Grad Fahrenheit liegen, obwohl die FDA dem Unternehmen kürzlich gestattet hat, ihn zwei Wochen lang bei Temperaturen zu lagern, die üblicherweise in pharmazeutischen Gefriergeräten zu finden sind. Moderna muss mit 13 unter null bis 5 Grad Fahrenheit verschickt werden.

Zuordnung zu Staaten

Jeff Zients, Covid-Zar von Präsident Joe Biden, sagte, dass der Impfstoff von J & J Staaten auf der Grundlage ihrer gesamten erwachsenen Bevölkerung zugeteilt wird – genau wie Pfizer und Moderna. Sobald der Impfstoff eingetroffen ist, können die Staaten die Dosen nach eigenem Ermessen verteilen, obwohl die CDC empfiehlt, die am stärksten gefährdeten Personen zu priorisieren.

In New York City sagte Bürgermeister Bill de Blasio, der J & J-Impfstoff sei für Senioren im Heimatland und andere bestimmt, die nicht einfach zu Vertriebszentren gelangen können. Er räumte ein, dass der Impfstoff aufgrund seiner geringeren Wirksamkeitsrate eine “Kommunikationsherausforderung” für staatliche und lokale Gesundheitsbehörden darstellen könnte.

“Es gibt viele Fehlinformationen, die wir überwinden müssen”, sagte er am 1. März gegenüber Reportern. “Sobald Sie geimpft sind, sind Sie geschützt. Es macht so viel Sinn, sie zu verwenden. Und das macht mir wirklich Sorgen.” Die Leute werden das falsche Verständnis davon bekommen und dann zögern, sich genau dann impfen zu lassen, wenn wir sie am dringendsten brauchen, um geimpft zu werden. “

In Louisville, Kentucky, sagten Gesundheitsbeamte, sie würden den Impfstoff für vorübergehende Menschen einsetzen, die einem hohen Risiko ausgesetzt sind und nicht einfach für einen zweiten Schuss zurückkehren können, wie die Obdachlosen. In Harris County, Texas, wo sich Houston befindet, wird der J & J-Impfstoff an mobilen Impfstellen verabreicht, die jede Woche den Standort wechseln, wenn Anbieter versuchen, unterversorgte Gruppen zu erreichen, die am anfälligsten für Covid sind.

Der Bürgermeister von Detroit, Mike Duggan, lehnte letzte Woche eine erste Zuteilung des Impfstoffs von J & J ab und sagte: “Johnson & Johnson ist ein sehr guter Impfstoff. Moderna und Pfizer sind die besten. Und ich werde alles tun, um sicherzustellen, dass die Bewohner der Stadt von Detroit bekommen das Beste. “

Später ging er diese Kommentare zurück und teilte CNBC in einer Erklärung mit, dass die Stadt bereits über genügend Kapazitäten mit Moderna und Pfizer verfügt, um Tausende von Einwohnern zu impfen. Er sagte, die Stadt werde eine neue Impfstelle für J & J-Aufnahmen eröffnen, wenn die Nachfrage der berechtigten Bewohner das Angebot an Moderna- und Pfizer-Dosen übersteigt.

“Sehr vorsichtig”

Kasisomayajula Viswanath, Professor für Gesundheitskommunikation an der Harvard TH Chan School of Public Health, sagte gegenüber CNBC, er sei besorgt darüber, wie Staaten den Impfstoff verteilen würden, auch wenn ihr Plan sinnvoll sei.

Viswanath, dessen Forschung sich auf die Beseitigung von Ungleichheiten im Gesundheitswesen konzentriert, sagte, dass staatliche und lokale Gesundheitsbehörden mitteilen müssen, warum der Impfstoff von J & J auf eine bestimmte Weise verteilt wird, oder dass sie Vorwürfe von Rassismus und Misstrauen riskieren.

“Wir müssen äußerst vorsichtig sein”, sagte er und fügte hinzu, dass die Impfstoffe von Moderna und Pfizer J & J überlegen seien.

Viswanath empfahl den Staaten, die Hilfe lokaler Organisationen, denen Gemeinschaften vertrauen, wie Kirchen oder Aktivistengruppen, für ihre Kommunikationsbemühungen zu gewinnen.

“Wenn Sie anfangen, diesen Impfstoff an bestimmte Gruppen und bestimmte Stadtteile zu verteilen, ohne zu erklären, warum dies so gemacht wird, besteht wahrscheinlich die Wahrnehmung, dass meine Gruppe, meine Nachbarschaft, meine Stadt diesen Impfstoff mit geringer Wirksamkeit im Vergleich zu erhält diese Gruppe, diese Nachbarschaft oder diese Stadt “, sagte er.

Insbesondere in schwarzen Gemeinden gibt es bereits Bedenken aufgrund der anhaltenden Diskriminierung, die sie “Tag für Tag” vom Gesundheitssystem erfahren, sagte er.

“Die tägliche Diskriminierung, die tägliche Respektlosigkeit, das ist es, was Misstrauen erzeugt”, sagte er.

Umdenken

Dr. Stephen Schrantz, der Teil des Teams war, das eine J & J-Impfstoffstudie an der Medizin der Universität von Chicago leitete, sagte, Kommunikation sei der Schlüssel. Er fügte hinzu, dass Anbieter nicht möchten, dass ihre Patienten glauben, sie würden “einen wirksameren Impfstoff erhalten als eine andere Person”.

Die Wahrnehmung der Menschen kann sich ändern, fügte er hinzu, zumal mehr Daten über die Impfstoffe herauskommen und die Menschen von den Menschen ihre eigenen inneren Kreise hören.

Veronica Takougang, eine schwarze Medizinstudentin im ersten Jahr in Cincinnati, sagte, sie habe von Gleichaltrigen und anderen viele Bedenken über den J & J-Impfstoff gehört und darüber, ob er vorwiegend in Farbgemeinschaften eingesetzt wird.

Sie sagte, dass sie den Menschen sagt, dass der Impfstoff viele Vorteile hat, einschließlich der Tatsache, dass er schwere Krankheiten verhindert und eine Einzeldosis darstellt, so dass etwa einen Monat später kein zweiter Termin vereinbart werden muss.

“Die Leute achten sehr auf die Zahlen”, sagte sie. Sie fügte hinzu, dass ihre Bedenken hinsichtlich des Impfstoffs von J & J “gültig” seien und dass Menschen nicht davon ausgeschlossen werden sollten, die anderen Impfstoffe zu erhalten, nur weil sie möglicherweise nicht in der Lage sind, eine zusätzliche Stunde frei zu nehmen.

Geimpft werden

Das Weiße Haus fordert die Öffentlichkeit auf, den ersten Impfstoff zu nehmen, den Sie bekommen können.

“Wir haben drei hochwirksame Impfstoffe mit einem sehr guten Sicherheitsprofil”, sagte Fauci am Freitag gegenüber Reportern. “Jeder von ihnen ist sehr wirksam bei der Vorbeugung klinisch offensichtlicher Krankheiten. Wichtig ist jedoch, dass alle drei einen sehr wichtigen Effekt haben, da sie außerordentlich wirksam gegen schwere Krankheiten sind und Krankenhausaufenthalte und Todesfälle verhindern.”

“Das Wichtigste ist, sich impfen zu lassen und nicht herauszufinden, ob einer besser ist als der andere”, fügte er hinzu.

Alex Gorsky, CEO von J & J bei CNBC, sprach am 1. März ebenfalls über die niedrigere Wirksamkeitsrate und sagte, der Impfstoff werde ein wichtiges Instrument im Kampf gegen das Virus sein, da er Krankenhausaufenthalte und Todesfälle verhindert.

“Es gibt viele verschiedene Möglichkeiten, Vergleiche anzustellen”, sagte Gorsky in einem Interview mit CNBCs “Squawk Box”. “Aber wenn man sich wirklich ansieht, was hier das Ziel ist, Menschen aus dem Krankenhaus herauszuhalten und Menschen vor dem Sterben zu bewahren, glauben wir, dass dies ein unglaublich wichtiges Instrument ist, das hinzugefügt werden muss – zu Gesundheitssystemen, geschweige denn zu Patienten auf der ganzen Welt.”

Categories
Health

Tilray inventory rallies on pot distribution settlement with Develop Pharma

Tilray shares rose 38.8% on Tuesday after the company signed an agreement with Grow Pharma to import and distribute its medical cannabis products in the UK.

Under the contract, Tilray will be able to make these products available to UK patients on prescriptions obtained through the country’s National Health Service or a general practitioner. The company expects these products to be available in the UK next month.

“This partnership with Grow Pharma provides patients in need with access to sustainable supplies of GMP-certified, high-quality medical cannabis and is an important step towards improving access in the UK,” said Brendan Kennedy, CEO of Tilray, in a statement.

Pierre van Weperen, CEO of Grow Pharma, also noted that the agreement will provide British patients with “safe and sustainable supply of the highest quality medical cannabis products”.

This deal is Tilray’s latest move to expand its market share in the cannabis space. In December, Tilray announced it would merge with Aphria in an all-stock deal to create the world’s largest cannabis company when the deal is closed.

Tilray shares were on fire this year, rising nearly 400% as demand for cannabis products grows in the US and around the world.

Categories
Business

Moderna asks FDA to authorize 5 further doses per Covid vaccine vial to hurry distribution, supply tells CNBC

A health care worker holds a vial of the Moderna COVID-19 vaccine at a pop-up vaccination station operated by SOMOS Community Care during the coronavirus disease (COVID-19) pandemic in New York on January 29, 2021 .

Facebook Facebook Logo Log in to Facebook to connect with Mike Segar Reuters

Moderna has asked the U.S. Food and Drug Administration for permission to fill their Covid-19 vaccine bottles with up to five additional doses to help clear a manufacturing bottleneck, according to a person familiar with the matter.

The change would allow Moderna to fill 15 cans into vials of the same size, now cleared for 10, which eases the pressure on the manufacturing process known as filling / finishing, said the person who refused to named because the application is not public yet.

The availability of Covid-19 vaccines has caused frustration since their approval in the US in mid-December. While the pace of administration has increased to an average of more than 1 million a day, the limited supply has hampered states’ ability to operate mass vaccination centers. By Friday, the US had distributed 49.2 million doses and 27.9 million had been given, according to the Centers for Disease Control and Prevention.

“We have problems making these mRNA vaccines,” said Dr. Paul Offit, director of the Vaccine Education Center and a physician at Philadelphia Children’s Hospital. “We have up to 1.2 million doses a day when we need 3 million doses a day.”

The FDA declined to comment and asked questions to the company. Moderna did not immediately respond to a request for comment.

The move from Moderna came after Pfizer requested and received a change in emergency approval from the FDA to specify that the Covid-19 vaccine bottles contain six doses instead of five after pharmacists determined that it had a bonus dose the correct syringes could be extracted. Pfizer then said it would ship fewer vials to the US, but the same number of doses specified in its contracts.

Moderna vials have also been found to contain a bonus dose, but a policy change is being sought to add volume to the vials.

The bottleneck is not the vials themselves, but the manufacturing capacity to fill the vials. The manufacturing filling / finishing process must be performed under aseptic conditions to ensure contamination does not occur and the capacity is high.

Companies have begun to form manufacturing partnerships that focus on this step in the process to increase production. Novartis announced on Friday that it has signed an initial vial fill agreement for BioNTech, Pfizer’s partner in Europe, for the Covid-19 vaccine.

“We expect this to be the first in a series of such agreements,” said Steffen Lang, head of technical operations at Novartis.

Categories
Business

Hospital group presses Trump administration for ongoing federal assist with vaccine distribution

Seniors 65 years and older wait in line at the Sarasota Department of Health’s COVID-19 Vaccination Clinic in Sarasota, Florida, the United States, Jan. 4, 2021.

Octavio Jones | Reuters

The American Hospital Association on Thursday urged Health Secretary Alex Azar to provide more support and coordination for the federal distribution of Covid-19 vaccines. The slow rollout has raised questions about how quickly they can vaccinate the public.

The group, which represents nearly 5,000 hospitals and health systems across the country, said the rollout “raised concerns about whether the task of vaccinating everyone who is able to take the vaccine will come as soon as it can it was suggested by the federal leaders “. According to a letter sent Thursday to Azar, the secretary of the Ministry of Health and Human Services.

According to the Centers for Disease Control and Prevention, more than 17.2 million doses of vaccine had been distributed as of Wednesday, but in fact just over 5.3 million doses had been given. This is nowhere near the targets previously set by federal officials to vaccinate 20 million people in December.

Richard Pollack, CEO of the AHA, said in the letter to Azar that the vaccine’s slow initial rollout casts doubt on whether the country will be able to vaccinate enough Americans to achieve herd immunity by the summer. In the first few weeks of the rollout, unforeseen issues arose, he added, calling on Azar to provide more leadership and coordination between states to address the issues.

Representatives from HHS have not returned CNBC’s request for comment.

According to Pollack, some hospitals have received fewer doses than requested, while others have received more than they need “with no explanation for this mismatch”. Pollack added that other differences between the state’s plans are also creating headaches for hospitals and adding to the complexity of the massive vaccination campaign.

“We hear from hospitals and health systems that serve more than one state that it is difficult to manage vaccine distribution when their patients live in jurisdictions with different rules about which patients are prioritized and who have different levels of priority,” wrote Pollack . “As this rollout is evolving rapidly, it is absolutely essential that effective situational real-time guidance is provided at the national level.”

He urged Azar and HHS to communicate more frequently and clearly with state, local, and hospital officials.

And many hospitals across the country are currently overwhelmed with treating Covid-19 patients. Pollack says hospitals cannot vaccinate the public without help. He said hospitals suffer from staff shortages and limited protective equipment such as masks and gloves. Pollack asked for more details about the government’s plan to include pharmacy chains in the wider vaccine rollout.

Pollack stressed that the aim of the vaccination campaign is to achieve herd immunity and bring the outbreak under control. By some estimates, that could be around 246 million Americans, or around 75% of the population.

“That would mean vaccinating 1.8 million people a day between January 15 and May 31, including weekends and holidays,” wrote Pollack of the attempt to vaccinate 246 million Americans by the summer. “There are currently 64 different micro-plans being developed by states, some major cities, and other jurisdictions [HHS] assess whether these plans are overall able to achieve this level of vaccination? “

Categories
Health

Why Coronavirus Vaccine Distribution is Taking Longer Than Anticipated

In Florida, less than one-quarter of delivered coronavirus vaccines have been used, even as older people sat in lawn chairs all night waiting for their shots. In Puerto Rico, last week’s vaccine shipments did not arrive until the workers who would have administered them had left for the Christmas holiday. In California, doctors are worried about whether there will be enough hospital staff members to both administer vaccines and tend to the swelling number of Covid-19 patients.

These sorts of logistical problems in clinics across the country have put the campaign to vaccinate the United States against Covid-19 far behind schedule in its third week, raising fears about how quickly the country will be able to tame the epidemic.

Federal officials said as recently as this month that their goal was to have 20 million people get their first shot by the end of this year. More than 14 million doses of the Pfizer and Moderna vaccines had been sent out across the United States, federal officials said on Wednesday. But, according to the Centers for Disease Control and Prevention, just 2.8 million people have received their first dose, though that number may be somewhat low because of lags in reporting.

States vary widely in how many of the doses they’ve received have been given out. South Dakota leads the country with more than 48 percent of its doses given, followed by West Virginia, at 38 percent. By contrast, Kansas has given out less than 11 percent of its doses, and Georgia, less than 14 percent.

Compounding the challenges, federal officials say they do not fully understand the cause of the delays. But state health officials and hospital leaders throughout the country pointed to several factors. States have held back doses to be given out to their nursing homes and other long-term-care facilities, an effort that is just gearing up and expected to take several months. Across the country, just 8 percent of the doses distributed for use in these facilities have been administered, with two million yet to be given.

The holiday season has meant that people are off work and clinics have reduced hours, slowing the pace of vaccine administration. In Florida, for example, the demand for the vaccines dipped over the Christmas holiday and is expected to dip again over New Year’s, Gov. Ron DeSantis said on Wednesday.

And critically, public health experts say, federal officials have left many of the details of the final stage of the vaccine distribution process, such as scheduling and staffing, to overstretched local health officials and hospitals.

In one notable blunder, forty-two people in Boone County, W.Va., who were scheduled to receive the coronavirus vaccine on Wednesday instead were mistakenly injected with an experimental monoclonal antibody treatment.

The West Virginia National Guard, which is leading the state’s vaccine distribution effort, called the error “a breakdown in the process.” None of the recipients has developed any adverse effects so far.

“We’ve taken the people with the least amount of resources and capacity and asked them to do the hardest part of the vaccination — which is actually getting the vaccines administered into people’s arms,” said Dr. Ashish Jha, the dean of Brown University’s School of Public Health.

Federal and state officials have denied they are to blame for the slow rollout. Officials behind Operation Warp Speed, the federal effort to fast-track vaccines, have said that their job was to ensure that vaccines are made available and get shipped out to the states. President Trump said in a tweet on Tuesday that it was “up to the States to distribute the vaccines once brought to the designated areas by the Federal Government.”

“Ultimately, the buck seems to stop with no one,” Dr. Jha said.

These problems are especially worrisome now that a new, more contagious variant, first spotted in Britain and overwhelming hospitals there, has arrived in the U.S. Officials in two states, Colorado and California, say they have discovered cases of the new variant, and none of the patients had recently traveled, suggesting the variant is already spreading in American communities.

The $900 billion relief package that Mr. Trump signed into law on Sunday will bring some relief to struggling state and local health departments. The bill sets aside more than $8 billion for vaccine distribution, on top of the $340 million that the C.D.C. sent out to the states in installments in September and earlier this month.

That infusion of money is welcome, if late, said Dr. Bob Wachter, a professor and chair of the department of medicine at the University of California, San Francisco. “Why did that take until now when we knew we were going to have this problem two months ago?”

Michael Pratt, a spokesman for Operation Warp Speed, said that there will always be lags between the number of doses that have been allocated, shipped, injected and reported. “We’re working to make those lags as small as possible,” Mr. Pratt said.

Covid-19 Vaccines ›

Answers to Your Vaccine Questions

With distribution of a coronavirus vaccine beginning in the U.S., here are answers to some questions you may be wondering about:

    • If I live in the U.S., when can I get the vaccine? While the exact order of vaccine recipients may vary by state, most will likely put medical workers and residents of long-term care facilities first. If you want to understand how this decision is getting made, this article will help.
    • When can I return to normal life after being vaccinated? Life will return to normal only when society as a whole gains enough protection against the coronavirus. Once countries authorize a vaccine, they’ll only be able to vaccinate a few percent of their citizens at most in the first couple months. The unvaccinated majority will still remain vulnerable to getting infected. A growing number of coronavirus vaccines are showing robust protection against becoming sick. But it’s also possible for people to spread the virus without even knowing they’re infected because they experience only mild symptoms or none at all. Scientists don’t yet know if the vaccines also block the transmission of the coronavirus. So for the time being, even vaccinated people will need to wear masks, avoid indoor crowds, and so on. Once enough people get vaccinated, it will become very difficult for the coronavirus to find vulnerable people to infect. Depending on how quickly we as a society achieve that goal, life might start approaching something like normal by the fall 2021.
    • If I’ve been vaccinated, do I still need to wear a mask? Yes, but not forever. Here’s why. The coronavirus vaccines are injected deep into the muscles and stimulate the immune system to produce antibodies. This appears to be enough protection to keep the vaccinated person from getting ill. But what’s not clear is whether it’s possible for the virus to bloom in the nose — and be sneezed or breathed out to infect others — even as antibodies elsewhere in the body have mobilized to prevent the vaccinated person from getting sick. The vaccine clinical trials were designed to determine whether vaccinated people are protected from illness — not to find out whether they could still spread the coronavirus. Based on studies of flu vaccine and even patients infected with Covid-19, researchers have reason to be hopeful that vaccinated people won’t spread the virus, but more research is needed. In the meantime, everyone — even vaccinated people — will need to think of themselves as possible silent spreaders and keep wearing a mask. Read more here.
    • Will it hurt? What are the side effects? The Pfizer and BioNTech vaccine is delivered as a shot in the arm, like other typical vaccines. The injection into your arm won’t feel different than any other vaccine, but the rate of short-lived side effects does appear higher than a flu shot. Tens of thousands of people have already received the vaccines, and none of them have reported any serious health problems. The side effects, which can resemble the symptoms of Covid-19, last about a day and appear more likely after the second dose. Early reports from vaccine trials suggest some people might need to take a day off from work because they feel lousy after receiving the second dose. In the Pfizer study, about half developed fatigue. Other side effects occurred in at least 25 to 33 percent of patients, sometimes more, including headaches, chills and muscle pain. While these experiences aren’t pleasant, they are a good sign that your own immune system is mounting a potent response to the vaccine that will provide long-lasting immunity.
    • Will mRNA vaccines change my genes? No. The vaccines from Moderna and Pfizer use a genetic molecule to prime the immune system. That molecule, known as mRNA, is eventually destroyed by the body. The mRNA is packaged in an oily bubble that can fuse to a cell, allowing the molecule to slip in. The cell uses the mRNA to make proteins from the coronavirus, which can stimulate the immune system. At any moment, each of our cells may contain hundreds of thousands of mRNA molecules, which they produce in order to make proteins of their own. Once those proteins are made, our cells then shred the mRNA with special enzymes. The mRNA molecules our cells make can only survive a matter of minutes. The mRNA in vaccines is engineered to withstand the cell’s enzymes a bit longer, so that the cells can make extra virus proteins and prompt a stronger immune response. But the mRNA can only last for a few days at most before they are destroyed.

The task of administering thousands of vaccines is daunting for health departments that have already been overburdened by responding to the pandemic. In Montgomery County, Maryland, the local health department has recruited extra staff to help manage vaccine distribution, said Travis Gayles, the county health officer.

“While we’re trying to roll out vaccinations, we’re also continuing the pandemic response by supporting testing, contact tracing, disease control and all of those other aspects of the Covid response,” Dr. Gayles said.

Complicating matters, the county health department gets just a few days of notice each week of the timing of its vaccine shipments. When the latest batch arrived, Dr. Gayles’s team scrambled to contact people eligible for the vaccine and to set up clinics to give out the doses as fast as possible.

Over all, Maryland has given nearly 17 percent of its vaccine doses. In a Wednesday appearance on CBS, Gov. Larry Hogan attributed the slow process to challenges across the board — from the federal government not sending as many doses as initially predicted, to the lack of logistical and financial support for local health departments.

In Texas, Gov. Greg Abbott and top state health officials say vaccines are available in the state but are not being distributed quickly enough to deal with a critical surge of Covid-19 cases that is pushing hospital capacity to the breaking point.

“A significant portion of vaccines distributed across Texas might be sitting on hospital shelves as opposed to being given to vulnerable Texans,” the governor tweeted Tuesday.

In California, Gov. Gavin Newsom on Wednesday encouraged people to be “humble” in the face of such a complicated task and said that the pace of vaccination would accelerate. California has administered 20 percent of the doses it’s received.

Hesitancy among people offered the vaccine may also be slowing the rollout. Gov. Mike DeWine of Ohio said in a news conference on Wednesday that roughly 60 percent of nursing home staff members offered the vaccine in the state had declined it. In Florida, some hospital workers offered the vaccine declined it, and those doses are now designated for other vulnerable groups like health care workers in the community and the elderly, but that rollout has not quite begun, said Justin Senior, chief executive officer for the Safety Net Hospital Alliance of Florida, a hospital consortium.

There are bright spots. Some states and hospitals are finding ways to speedily administer the vaccines they have received. West Virginia said on Wednesday that it had finished giving the first round of vaccine doses to willing residents and workers at all of the state’s 214 long-term-care facilities — putting the state far ahead of most other states that began vaccinating at these facilities under a federal program with CVS and Walgreens.

In Los Angeles, Cedars-Sinai Medical Center, which employs some 20,000 people at several facilities, was vaccinating about 800 people a day, said Dr. Jeff Smith, Cedars-Sinai’s chief operating officer. He said Cedars-Sinai expected to vaccinate all of its staff members who have opted for the vaccine within a couple of weeks.

But other communities are falling short of that rapid clip. Dr. Smith said the medical community is worried about staffing shortages when hospitals have to both administer vaccines and treat Covid-19 patients.

In a news conference on Wednesday, Operation Warp Speed officials said they expected the pace of the rollout to accelerate significantly once pharmacies begin offering vaccines in their stores. The federal government has reached agreements with a number of pharmacy chains — including Costco, Walmart, and CVS — to administer vaccines once they become more widely available. So far, 40,000 pharmacy locations have enrolled in that program.

Most vaccines administered across the country to date have been given to health care workers at hospitals and clinics, and to older adults at nursing homes. Gen. Gustave F. Perna, the logistics lead of Operation Warp Speed, on Wednesday described them as “two very difficult, challenging groups” to immunize.

But public health officials warned that reaching these initial groups, who are largely being vaccinated where they live or work, is a relatively easy task. “This is the part where we’re supposed to know where people are,” said Dr. Saad B. Omer, the director of the Yale Institute for Global Health.

It may be more difficult, public health officials say, to vaccinate the next wave of people, which will most likely include many more older Americans as well as younger people with health problems and frontline workers. Among the fresh challenges: How will these people be scheduled for their vaccination appointments? How will they provide documentation that they have a medical condition or a job that makes them eligible to get vaccinated? And how will pharmacies ensure that people show up, and that they can do so safely?

“In the next phase,” said Dr. Jha of Brown University, “we’re going to hit the same wall, where all of a sudden we’re going to have to scramble to start figuring it out.”

Lucy Tompkins and David Montgomery contributed reporting.

Categories
Health

Right here’s Why the ‘Final Mile’ of Vaccine Distribution Is Going So Slowly

In Florida, less than one-quarter of delivered coronavirus vaccines have been used, even as older people sat in lawn chairs all night waiting for their shots. In Puerto Rico, last week’s vaccine shipments did not arrive until the workers who would have administered them had left for the Christmas holiday. In California, doctors are worried about whether there will be enough hospital staff members to both administer vaccines and tend to the swelling number of Covid-19 patients.

These sorts of logistical problems in clinics across the country have put the campaign to vaccinate the United States against Covid-19 far behind schedule in its third week, raising fears about how quickly the country will be able to tame the epidemic.

Federal officials said as recently as this month that their goal was to have 20 million people get their first shot by the end of this year. More than 14 million doses of the Pfizer and Moderna vaccines had been sent out across the United States, federal officials said on Wednesday. But, according to the Centers for Disease Control and Prevention, just 2.8 million people have received their first dose, though that number may be somewhat low because of lags in reporting.

States vary widely in how many of the doses they’ve received have been given out. South Dakota leads the country with more than 48 percent of its doses given, followed by West Virginia, at 38 percent. By contrast, Kansas has given out less than 11 percent of its doses, and Georgia, less than 14 percent.

Compounding the challenges, federal officials say they do not fully understand the cause of the delays. But state health officials and hospital leaders throughout the country pointed to several factors. States have held back doses to be given out to their nursing homes and other long-term-care facilities, an effort that is just gearing up and expected to take several months. Across the country, just 8 percent of the doses distributed for use in these facilities have been administered, with two million yet to be given.

The holiday season has meant that people are off work and clinics have reduced hours, slowing the pace of vaccine administration. In Florida, for example, the demand for the vaccines dipped over the Christmas holiday and is expected to dip again over New Year’s, Gov. Ron DeSantis said on Wednesday.

And critically, public health experts say, federal officials have left many of the details of the final stage of the vaccine distribution process, such as scheduling and staffing, to overstretched local health officials and hospitals.

“We’ve taken the people with the least amount of resources and capacity and asked them to do the hardest part of the vaccination — which is actually getting the vaccines administered into people’s arms,” said Dr. Ashish Jha, the dean of Brown University’s School of Public Health.

Federal and state officials have denied they are to blame for the slow rollout. Officials behind Operation Warp Speed, the federal effort to fast-track vaccines, have said that their job was to ensure that vaccines are made available and get shipped out to the states. President Trump said in a tweet on Tuesday that it was “up to the States to distribute the vaccines once brought to the designated areas by the Federal Government.”

“Ultimately, the buck seems to stop with no one,” Dr. Jha said.

These problems are especially worrisome now that a new, more contagious variant, first spotted in Britain and overwhelming hospitals there, has arrived in the U.S. Officials in two states, Colorado and California, say they have discovered cases of the new variant, and none of the patients had recently traveled, suggesting the variant is already spreading in American communities.

The $900 billion relief package that Mr. Trump signed into law on Sunday will bring some relief to struggling state and local health departments. The bill sets aside more than $8 billion for vaccine distribution, on top of the $340 million that the C.D.C. sent out to the states in installments in September and earlier this month.

That infusion of money is welcome, if late, said Dr. Bob Wachter, a professor and chair of the department of medicine at the University of California, San Francisco. “Why did that take until now when we knew we were going to have this problem two months ago?”

Covid-19 Vaccines ›

Answers to Your Vaccine Questions

With distribution of a coronavirus vaccine beginning in the U.S., here are answers to some questions you may be wondering about:

    • If I live in the U.S., when can I get the vaccine? While the exact order of vaccine recipients may vary by state, most will likely put medical workers and residents of long-term care facilities first. If you want to understand how this decision is getting made, this article will help.
    • When can I return to normal life after being vaccinated? Life will return to normal only when society as a whole gains enough protection against the coronavirus. Once countries authorize a vaccine, they’ll only be able to vaccinate a few percent of their citizens at most in the first couple months. The unvaccinated majority will still remain vulnerable to getting infected. A growing number of coronavirus vaccines are showing robust protection against becoming sick. But it’s also possible for people to spread the virus without even knowing they’re infected because they experience only mild symptoms or none at all. Scientists don’t yet know if the vaccines also block the transmission of the coronavirus. So for the time being, even vaccinated people will need to wear masks, avoid indoor crowds, and so on. Once enough people get vaccinated, it will become very difficult for the coronavirus to find vulnerable people to infect. Depending on how quickly we as a society achieve that goal, life might start approaching something like normal by the fall 2021.
    • If I’ve been vaccinated, do I still need to wear a mask? Yes, but not forever. Here’s why. The coronavirus vaccines are injected deep into the muscles and stimulate the immune system to produce antibodies. This appears to be enough protection to keep the vaccinated person from getting ill. But what’s not clear is whether it’s possible for the virus to bloom in the nose — and be sneezed or breathed out to infect others — even as antibodies elsewhere in the body have mobilized to prevent the vaccinated person from getting sick. The vaccine clinical trials were designed to determine whether vaccinated people are protected from illness — not to find out whether they could still spread the coronavirus. Based on studies of flu vaccine and even patients infected with Covid-19, researchers have reason to be hopeful that vaccinated people won’t spread the virus, but more research is needed. In the meantime, everyone — even vaccinated people — will need to think of themselves as possible silent spreaders and keep wearing a mask. Read more here.
    • Will it hurt? What are the side effects? The Pfizer and BioNTech vaccine is delivered as a shot in the arm, like other typical vaccines. The injection into your arm won’t feel different than any other vaccine, but the rate of short-lived side effects does appear higher than a flu shot. Tens of thousands of people have already received the vaccines, and none of them have reported any serious health problems. The side effects, which can resemble the symptoms of Covid-19, last about a day and appear more likely after the second dose. Early reports from vaccine trials suggest some people might need to take a day off from work because they feel lousy after receiving the second dose. In the Pfizer study, about half developed fatigue. Other side effects occurred in at least 25 to 33 percent of patients, sometimes more, including headaches, chills and muscle pain. While these experiences aren’t pleasant, they are a good sign that your own immune system is mounting a potent response to the vaccine that will provide long-lasting immunity.
    • Will mRNA vaccines change my genes? No. The vaccines from Moderna and Pfizer use a genetic molecule to prime the immune system. That molecule, known as mRNA, is eventually destroyed by the body. The mRNA is packaged in an oily bubble that can fuse to a cell, allowing the molecule to slip in. The cell uses the mRNA to make proteins from the coronavirus, which can stimulate the immune system. At any moment, each of our cells may contain hundreds of thousands of mRNA molecules, which they produce in order to make proteins of their own. Once those proteins are made, our cells then shred the mRNA with special enzymes. The mRNA molecules our cells make can only survive a matter of minutes. The mRNA in vaccines is engineered to withstand the cell’s enzymes a bit longer, so that the cells can make extra virus proteins and prompt a stronger immune response. But the mRNA can only last for a few days at most before they are destroyed.

The task of administering thousands of vaccines is daunting for health departments that have already been overburdened by responding to the pandemic. In Montgomery County, Maryland, the local health department has recruited extra staff to help manage vaccine distribution, said Travis Gayles, the county health officer.

“While we’re trying to roll out vaccinations, we’re also continuing the pandemic response by supporting testing, contact tracing, disease control and all of those other aspects of the Covid response,” Dr. Gayles said.

Complicating matters, the county health department gets just a few days of notice each week of the timing of its vaccine shipments. When the latest batch arrived, Dr. Gayles’s team scrambled to contact people eligible for the vaccine and to set up clinics to give out the doses as fast as possible.

Over all, Maryland has given nearly 17 percent of its vaccine doses. In a Wednesday appearance on CBS, Gov. Larry Hogan attributed the slow process to challenges across the board — from the federal government not sending as many doses as initially predicted, to the lack of logistical and financial support for local health departments.

In Texas, Gov. Greg Abbott and top state health officials say vaccines are available in the state but are not being distributed quickly enough to deal with a critical surge of Covid-19 cases that is pushing hospital capacity to the breaking point.

“A significant portion of vaccines distributed across Texas might be sitting on hospital shelves as opposed to being given to vulnerable Texans,” the governor tweeted Tuesday.

In California, Gov. Gavin Newsom on Wednesday encouraged people to be “humble” in the face of such a complicated task and said that the pace of vaccination would accelerate. California has administered 20 percent of the doses it’s received.

Hesitancy among people offered the vaccine may also be slowing the rollout. Gov. Mike DeWine of Ohio said in a news conference on Wednesday that roughly 60 percent of nursing home staff members offered the vaccine in the state had declined it. In Florida, some hospital workers offered the vaccine declined it, and those doses are now designated for other vulnerable groups like health care workers in the community and the elderly, but that rollout has not quite begun, said Justin Senior, chief executive officer for the Safety Net Hospital Alliance of Florida, a hospital consortium.

There are bright spots. Some states and hospitals are finding ways to speedily administer the vaccines they have received. West Virginia said on Wednesday that it had finished giving the first round of vaccine doses to willing residents and workers at all of the state’s 214 long-term-care facilities — putting the state far ahead of most other states that began vaccinating at these facilities under a federal program with CVS and Walgreens.

In Los Angeles, Cedars-Sinai Medical Center, which employs some 20,000 people at several facilities, was vaccinating about 800 people a day, said Dr. Jeff Smith, Cedars-Sinai’s chief operating officer. He said Cedars-Sinai expected to vaccinate all of its staff members who have opted for the vaccine within a couple of weeks.

But other communities are falling short of that rapid clip. Dr. Smith said the medical community is worried about staffing shortages when hospitals have to both administer vaccines and treat Covid-19 patients.

In a news conference on Wednesday, Operation Warp Speed officials said they expected the pace of the rollout to accelerate significantly once pharmacies begin offering vaccines in their stores. The federal government has reached agreements with a number of pharmacy chains — including Costco, Walmart, and CVS — to administer vaccines once they become more widely available. So far, 40,000 pharmacy locations have enrolled in that program.

Most vaccines administered across the country to date have been given to health care workers at hospitals and clinics, and to older adults at nursing homes. Gen. Gustave F. Perna, the logistics lead of Operation Warp Speed, on Wednesday described them as “two very difficult, challenging groups” to immunize.

But public health officials warned that reaching these initial groups, who are largely being vaccinated where they live or work, is a relatively easy task. “This is the part where we’re supposed to know where people are,” said Dr. Saad B. Omer, the director of the Yale Institute for Global Health.

It may be more difficult, public health officials say, to vaccinate the next wave of people, which will most likely include many more older Americans as well as younger people with health problems and frontline workers. Among the fresh challenges: How will these people be scheduled for their vaccination appointments? How will they provide documentation that they have a medical condition or a job that makes them eligible to get vaccinated? And how will pharmacies ensure that people show up, and that they can do so safely?

“In the next phase,” said Dr. Jha of Brown University, “we’re going to hit the same wall, where all of a sudden we’re going to have to scramble to start figuring it out.”

Lucy Tompkins and David Montgomery contributed reporting.